Reading Time: 4 minutes A recent paper published in Brain Communications has identified several lipid (fat-like) molecules that are elevated in MND, specifically amyotrophic lateral sclerosis (ALS) which is the most common form of MND. The study measured the levels of lipids in the blood of people living with ALS and how their lipid levels changed with time during…
Reading Time: 4 minutes Diagnosing disease faster, accurately predicting disease progression, assessing the ability of a new drug to reach its target – I think we’d all agree that these three things are essential requirements for treating all diseases. But how can we achieve this? The answer may lie in biomarkers. In his plenary talk at last year’s International…
Reading Time: 4 minutes This is blog number 15 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page may take a minute to load). There is currently no…
Reading Time: 7 minutes This is blog number 13 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page may take a minute to load). You can also find…
Reading Time: 9 minutes A paper arising from research carried out at the University of Sheffield as part of the AMBRoSIA biobank, and in collaboration with the international Project MinE gene-hunting consortium, was recently published in the Journal of Neurology, Neurosurgery and Psychiatry. Researchers propose that a test for the most common MND genes could be offered to all…
Reading Time: 4 minutes This blog is part of the ‘Virtual Highlights’ collection of articles, where you can read about the content of some of the talks and posters presented at the Virtual 31st International Symposium on ALS/MND. This presentation was part of Session 3: Clinical Trials Co-presented by Dr Merit Cudkowicz, from Harvard Medical School and Massachusetts General…
Reading Time: 4 minutes Recently published results from the open-label Lighthouse trial investigating safety of the drug Triumeq in people with MND revealed the treatment was safe and ready to progress to a larger Phase 3 clinical trial. The trial was held in Australia and recruited 40 people with MND who all received the active drug; this was because…
Reading Time: 10 minutes “The annals of ALS clinical trials is strewn with failed studies. Only two out of more than 70 clinical trials have been positive, and even these showed only very modest benefit. Is this dismal record strictly due to the extraordinary complexity of neurodegenerative disease in general, and ALS in particular? Or is it due to…
Reading Time: 3 minutes This blog is part of the ‘Highlights from Glasgow’ collection of articles, where you can read about the content of some of the talks and posters presented at the 29th International Symposium on ALS/MND. Around the globe, teams are working to find tissue biomarkers for MND and there some promising candidates coming through, some of…
Reading Time: 7 minutes In the last decade, the MND Association has invested millions in research within the UK and across the world. We are a leader in the funding and promotion of cutting-edge MND research and, with over 30 years experience of identifying the most promising projects, we only fund and support scientific and medical research of the…
